IQVIA, a leading company in clinical trials, has chosen Humanitas for a number of new research collaborations. The IRCCS Istituto Clinico Humanitas directed by Prof. Alberto Mantovani is a highly specialized hospital, a worldwide reference point for research on diseases related to the immune system thanks to Humanitas University, a university dedicated to Life Sciences. Within the polyclinic there are specialized centers for the treatment of cancer, cardiovascular, neurological, orthopedic, autoimmune and inflammatory diseases.


Humanitas among the selected Italian excellences

The clinical institute of Rozzano (MI) is one of only two Italian institutions selected for the first time by IQVIA, whose ‘prime sites’ are represented by a limited number of large clinical centers worldwide, characterized by a management sensitive to research issues and motivated to increase participation in clinical studies.

Through this partnership, which has also involved the IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, IQVIA helps patients access the most innovative therapies.

“Humanitas – explains CEO Luciano Ravera – is recognized as a center of excellence and reference in Italy for clinical research, at the forefront in bringing new therapeutic opportunities to the bed of patients thanks to its Phase I Unit. The collaboration with IQVIA allows us to further develop our clinical research horizons, both by strengthening the pipeline of studies in areas already consolidated for us, such as onco-hematology and immunology, and by involving further clinical areas”.

Humanitas and the Policlinico di Milano stand out for their excellence in the management of clinical trials, offering their patients the best therapies available and following the highest national and international quality standards. For this reason, they are excellent partners for the development of innovative drugs and for the experimentation of new therapeutic strategies.

“The choice of two Italian excellences, such as the Policlinico di Milano and Humanitas, is of fundamental importance for our country, first of all for the economic system, because innovation in medicine means qualified jobs, stimulating young people to get closer to science and consequent economic growth,” said Sergio Liberatore, CEO of IQVIA Italy. “Furthermore, investment in clinical research represents an advantage for the entire healthcare system, which benefits from the resources put in place by the pharmaceutical industry. Early access to experimental drugs, and the consequent development of knowledge about the pathology studied, are often crucial for the patient. The common goal is to obtain reliable data and ensure innovative medicines for patients as soon as possible. This agreement represents an opportunity to improve patients’ access to new therapies.